PMID- 35003126
OWN - NLM
STAT- MEDLINE
DCOM- 20220228
LR  - 20220228
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
PG  - 800630
LID - 10.3389/fimmu.2021.800630 [doi]
LID - 800630
AB  - Tumorigenesis is a complex multifactorial and multistep process in which tumors 
      can utilize a diverse repertoire of immunosuppressive mechanisms to evade host 
      immune attacks. The degradation of tryptophan into immunosuppressive kynurenine 
      is considered an important immunosuppressive mechanism in the tumor 
      microenvironment. There are three enzymes, namely, tryptophan 2,3-dioxygenase 
      (TDO), indoleamine 2,3-dioxygenase 1 (IDO1), and indoleamine 2,3-dioxygenase 2 
      (IDO2), involved in the metabolism of tryptophan. IDO1 has a wider distribution 
      and higher activity in catalyzing tryptophan than the other two; therefore, it 
      has been studied most extensively. IDO1 is a cytosolic monomeric, heme-containing 
      enzyme, which is now considered an authentic immune regulator and represents one 
      of the promising drug targets for tumor immunotherapy. Collectively, this review 
      highlights the regulation of IDO1 gene expression and the ambivalent mechanisms 
      of IDO1 on the antitumoral immune response. Further, new therapeutic targets via 
      the regulation of IDO1 are discussed. A comprehensive analysis of the expression 
      and biological function of IDO1 can help us to understand the therapeutic 
      strategies of the inhibitors targeting IDO1 in malignant tumors.
CI  - Copyright (c) 2021 Song, Si, Qi, Liu, Li, Guo, Wei and Yao.
FAU - Song, Xiaotian
AU  - Song X
AD  - Department of Immunology, Hebei Medical University, Shijiazhuang, China.
AD  - Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei 
      Province, Shijiazhuang, China.
FAU - Si, Qianqian
AU  - Si Q
AD  - Department of Immunology, Hebei Medical University, Shijiazhuang, China.
AD  - Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei 
      Province, Shijiazhuang, China.
FAU - Qi, Rui
AU  - Qi R
AD  - Department of Immunology, Hebei Medical University, Shijiazhuang, China.
AD  - Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei 
      Province, Shijiazhuang, China.
FAU - Liu, Weidan
AU  - Liu W
AD  - Department of Clinical Laboratory, The People's Hospital, Pingxiang County, 
      Xingtai, China.
FAU - Li, Miao
AU  - Li M
AD  - Department of Immunology, Hebei Medical University, Shijiazhuang, China.
AD  - Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei 
      Province, Shijiazhuang, China.
FAU - Guo, Mengyue
AU  - Guo M
AD  - Department of Immunology, Hebei Medical University, Shijiazhuang, China.
AD  - Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei 
      Province, Shijiazhuang, China.
FAU - Wei, Lin
AU  - Wei L
AD  - Department of Immunology, Hebei Medical University, Shijiazhuang, China.
AD  - Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei 
      Province, Shijiazhuang, China.
FAU - Yao, Zhiyan
AU  - Yao Z
AD  - Department of Immunology, Hebei Medical University, Shijiazhuang, China.
AD  - Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei 
      Province, Shijiazhuang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20211223
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (IDO1 protein, human)
RN  - 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase)
RN  - 8DUH1N11BX (Tryptophan)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Immune Tolerance
MH  - Indoleamine-Pyrrole 2,3,-Dioxygenase/*metabolism
MH  - Molecular Targeted Therapy
MH  - Neoplasms/*immunology
MH  - Tryptophan/*metabolism
MH  - Tumor Microenvironment
PMC - PMC8733291
OTO - NOTNLM
OT  - IDO1
OT  - immunotherapy
OT  - kynurenine
OT  - tryptophan
OT  - tumor immune escape
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/11 06:00
MHDA- 2022/03/01 06:00
PMCR- 2021/01/01
CRDT- 2022/01/10 09:11
PHST- 2021/10/23 00:00 [received]
PHST- 2021/12/03 00:00 [accepted]
PHST- 2022/01/10 09:11 [entrez]
PHST- 2022/01/11 06:00 [pubmed]
PHST- 2022/03/01 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.800630 [doi]
PST - epublish
SO  - Front Immunol. 2021 Dec 23;12:800630. doi: 10.3389/fimmu.2021.800630. eCollection 
      2021.